Lonza Biologics Plc is a specialized pharmaceutical contract development and manufacturing organization (CDMO) based in Switzerland, operating globally. Established in 1992, Lonza Biologics has evolved into a leading provider of custom development and manufacturing services for biopharmaceutical products. The company focuses on supporting clients throughout the entire lifecycle of drug development and commercialization, from early-stage research to commercial-scale production. Lonza Biologics’ core competencies lie in complex biologics, including cell and gene therapies, antibody-drug conjugates, and plasma-derived therapies. They offer a broad range of services encompassing process development, analytical testing, formulation, and large-scale manufacturing. The company’s expertise spans various therapeutic areas, including oncology, immunology, and rare diseases. Lonza Biologics operates internationally, with a significant presence in North America, Europe, and Asia. The company employs a diverse workforce of scientists, engineers, and technicians, and actively recruits skilled professionals. Lonza Biologics is a publicly traded company (Reg: 02742471) and is currently active. SIC codes include: - 96090: Other service activities n.e.c. The company’s website provides detailed information about its services and capabilities.

Lonza Biologics Plc is a specialized pharmaceutical contract development and manufacturing organization (CDMO) based in Switzerland, operating globally. Established in 1992, Lonza Biologics has evolved into a leading provider of custom development and manufacturing services for biopharmaceutical products. The company focuses on supporting clients throughout the entire lifecycle of drug development and commercialization, from early-stage research to commercial-scale production. Lonza Biologics’ core competencies lie in complex biologics, including cell and gene therapies, antibody-drug conjugates, and plasma-derived therapies. They offer a broad range of services encompassing process development, analytical testing, formulation, and large-scale manufacturing. The company’s expertise spans various therapeutic areas, including oncology, immunology, and rare diseases. Lonza Biologics operates internationally, with a significant presence in North America, Europe, and Asia. The company employs a diverse workforce of scientists, engineers, and technicians, and actively recruits skilled professionals. Lonza Biologics is a publicly traded company (Reg: 02742471) and is currently active. SIC codes include: - 96090: Other service activities n.e.c. The company’s website provides detailed information about its services and capabilities.